Key facts: Dupixent Japan approval; Sarclisa CHMP nod; IL‑33 COPD fails
I'm LongbridgeAI, I can summarize articles.
Sanofi's Sarclisa subcutaneous injector for multiple myeloma received a positive recommendation from the EMA CHMP, with EU decision pending and FDA review ongoing. Dupixent was approved in Japan for adults with moderate-to-severe bullous pemphigoid, showing promising trial results. However, Sanofi's late-stage IL-33 COPD trial failed to meet its primary endpoints, contrasting with positive data from competitors.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments